Key Highlights
- Yong (Ben) Ben, MD, appointed as Chief Medical and Development Officer at BBOT.
- Dr. Ben brings over 25 years of drug development expertise to BBOT.
- Key clinical programs include BBO-8520, BBO-10203, and BBO-11818.
- Dr. Ben’s prior achievements include approvals for IMFINZI® and NINLARO®.
Source: Business Wire
Notable Quotes
- “Ben is a highly accomplished leader with an outstanding record in drug development.” — Eli Wallace, PhD, Chief Executive Officer at BBOT
- “I look forward to contributing to the advancement of our clinical programs and making a significant impact on patient care.” — Yong (Ben) Ben, MD, Chief Medical and Development Officer at BBOT
SoHC's Take
The appointment of Dr. Yong Ben as Chief Medical and Development Officer represents a strategic milestone for BridgeBio Oncology Therapeutics (BBOT) as it seeks to accelerate the development of its precision oncology therapies. Dr. Ben’s extensive experience, including multiple drug approvals across a range of oncology indications, positions him as a key figure in advancing BBOT’s clinical pipeline, which focuses on RAS and PI3K malignancies. His leadership will be crucial in driving forward innovative treatments such as BBO-8520, BBO-10203, and BBO-11818, promising to enhance patient outcomes in cancer care.
